The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESH MM 2018 | MRD as a response assessment in elderly multiple myeloma
Measurable residual disease (MRD) is gaining traction as a tool for response assessment, prognosis and clinical decision making in the field of hem-onc; could it be particularly useful in the management of elderly multiple myeloma? We spoke to Alessandra Larocca, MD, PhD, of the University Hospital Città della Salute e della Scienza, Torino, Italy, on just that at the European School of Haematology (ESH) International Conference on Multiple Myeloma 2018, held in Mandelieu, France.
